Clinical trial
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
NCT00412581 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00412581 |
|---|---|
| Title | Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma |
| Official title | Phase I Safety Study of the Combination of Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy (CC-5013-MEL-003) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Lenalidomide, Dacarbazine |
| Enrollment | 28 |
| Start date | Sep 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Dec 18, 2006 |
| Last update posted | Apr 29, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: